DOR adjourn meeting to Jan. 24, 2007
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION`
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): December
29, 2006
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1101
Brickell Ave., Suite 701-S
Miami,
FL
|
|
33131
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(786)
425-3848
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 8.01. Other
Events.
On
December 29, 2006, due to the absence of a quorum, DOR BioPharma, Inc. (the
“Company”) adjourned its 2006 annual meeting of stockholders to January 24, 2007
at 10:30 a.m., Eastern Time, at the
J.W.
Marriott on the 5th Floor, 1109 Brickell Avenue, Miami, FL 33131.
The
preceding information is intended to be furnished only and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall
be
expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By: /s/
Christopher J. Schaber
Name:
Christopher J. Schaber, Ph.D.
Title:
President and Chief Executive Officer
Date:
December 29,
2006